Summit Therapeutics cancer therapy succeeds in late-stage China study

Summit Therapeutics

30/05/2024 20:30

May 30 (Reuters) - Summit Therapeutics  SMMT.O  said on
Thursday its experimental therapy to treat patients with a type
of lung cancer met the main goal of a late-stage study conducted
in China.
    The company said its therapy showed statistically
significant improvement compared to Merck's  MRK.N  Keytruda in
a head-to-head setting.
    Shares of the company more than doubled to $7.48. 
     

 (Reporting by Sneha  S K in Bengaluru; Editing by Arun Koyyur)
 ((Sneha.SK@thomsonreuters.com;))